Breathing with Amyotrophic Lateral Sclerosis

NCT ID: NCT05819931

Last Updated: 2025-01-08

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: NA
• Total Enrollment: 36 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2023-08-29
• Study Completion Date: 2026-12-31

Brief Summary

The study aims to evaluate the effect of mechanical insufflator-exsufflator on the respiratory functions of Amyotrophic Lateral Sclerosis (ALS) patients evaluated via peak expiratory flow on cough (PEFC) measurements. The evolution of their PEFC is monitored to see if the curative management can have a positive impact on the latter.

Detailed Description

Amyotrophic Lateral Sclerosis (ALS) is a rare neurodegenerative pathology without curative treatment at present, the outcome is fatal after 3 to 5 years of evolution on average. The disease results in progressive paralysis of the muscles involved in voluntary motricity (progressive and intricate impairment of locomotor, phonation and swallowing capacities as well as ventilatory function). In France, the management of ALS is based on a diversified multidisciplinary follow-up (physiotherapy, speech therapy, occupational therapy, neuropsychology) in the ALS Reference Center in conjunction with the city care networks. It is centered on the evaluation, and the early compensation of the various symptoms, especially the respiratory problems.

Thus, this study aims to evaluate the effect of mechanical insufflator-exsufflator on the respiratory functions of these patients, evaluated via cough peak expiratory flow measurements (CPEF).

The study is conducted in collaboration with the physiotherapists of each patient enrolled, to evaluate the respiratory function by peak expiratory flow on cough (PEFC) after 4 weeks of treatment with Mechanical In-Exsufflator (MIE) (3 weekly sessions for two weeks, then one daily session for 2 weeks) in ALS patients presenting with a poorly effective cough (PEFC between 160 and 255 L/min) and having an indication of punctual MIE.

Conditions

Amyotrophic Lateral Sclerosis

Study Design

• Allocation Method: NA
• Intervention Model: SEQUENTIAL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Mechanical In-Exsufflator treatment

Group Type: EXPERIMENTAL

Mechanical In-Exsufflator treatment

Intervention Type: DEVICE

The Mechanical In-Exsufflator (MIE) is a device that alternately inhales and exhales air and amplifies the respiratory cycles in flow and pressure. 15 breathing cycles (about 3 minutes) are recommended each day.

Patients will practice the MIE daily independently and/or carried out by his physiotherapist (PT) during PT sessions.

The MIE is prescribed by the neurologist or pulmonologist and is covered by social security in France. It is gifted by an external service provider.

The Peak-Flow Cough is considered as the standardized score retaining the best of 3 consecutive measurements by Peak-Flow, a small portable device for personal use, which measures the maximum expiratory flow reached by the patient at the moment when the breath is most powerful.

The patient is his own control. At baseline, the patient will be treated as usual. He will be asked to read the Peak-Flow Cough measures. The PT will also perform the Peak flow measurement at each patient visit.

Interventions

Mechanical In-Exsufflator treatment

The Mechanical In-Exsufflator (MIE) is a device that alternately inhales and exhales air and amplifies the respiratory cycles in flow and pressure. 15 breathing cycles (about 3 minutes) are recommended each day.

Patients will practice the MIE daily independently and/or carried out by his physiotherapist (PT) during PT sessions.

The MIE is prescribed by the neurologist or pulmonologist and is covered by social security in France. It is gifted by an external service provider.

The Peak-Flow Cough is considered as the standardized score retaining the best of 3 consecutive measurements by Peak-Flow, a small portable device for personal use, which measures the maximum expiratory flow reached by the patient at the moment when the breath is most powerful.

The patient is his own control. At baseline, the patient will be treated as usual. He will be asked to read the Peak-Flow Cough measures. The PT will also perform the Peak flow measurement at each patient visit.

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

• Confirmed ALS categorized as probable or certain according to the revised Awaji-Shima criteria [27].
• ALS of spinal, bulbar or respiratory forms
• Peak Flow measure between 160 and 255 L/min (recommendation of MIE in case of congestion, with the possibility of daily sessions)
• Patient who has not benefited from treatment by MIE in the past year (less than 10 sessions in total)
• Patient able to use the MIE and perform the collection, or having a caregiver able to help
• Patient receiving physiotherapist treatment greater than or equal to twice a week

Exclusion Criteria

• Psychiatric (DSM-5) or cognitive disorders incompatible with participation in the study
• Contraindication to the use of an MIE (pneumothorax for example)
• Insufficient level in French for understanding the study and completing the questionnaires
• Current or past participation in another innovative research or care program relating to respiratory functions
• Emergency situation for which the MIE must be set up within less than a week

Exclusion during the study :

• Appearance of a serious contraindication to the practice of MIE during the study (for example rib fracture during a fall)
• Patient's physiotherapist refusing to do the study

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 100 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

University Hospital, Toulouse

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Thierry Lagarde

Role: PRINCIPAL_INVESTIGATOR

University Hospital, Toulouse

Locations

SLA Center - Purpan University Hospital Toulouse, FRANCE

Toulouse, Occitanie, France

Site Status: RECRUITING

Countries

France

Central Contacts

Thierry LAGARDE, PT

Role: CONTACT

lagarde.t@chu-toulouse.fr

+33561775570

Floriane LLORENS

Role: CONTACT

llorens.fl@chu-toulouse.fr

Facility Contacts

Floriane LLORENS

Role: primary

llorens.fl@chu-toulouse.fr

Other Identifiers

RC31/22/0411

Identifier Type: -

Identifier Source: org_study_id